Cite
HARVARD Citation
Thier, B. et al. (n.d.). L5 RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodies. Journal for immunotherapy of cancer. p. A3. [Online].